The Impact of Known Heart Disease on Long-Term Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: A Multicenter International Study

S Prabhu; LH Ling; W Ullah; RJ Hunter; RJ Schilling; AJA McLellan; MJ Earley; SC Sporton; A Voskoboinik; D Blusztein; JA Mariani; G Lee; AJ Taylor; JM Kalman; PM Kistler

Journal article

The Impact of Known Heart Disease on Long-Term Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: A Multicenter International Study

S Prabhu, LH Ling, W Ullah, RJ Hunter, RJ Schilling, AJA McLellan, MJ Earley, SC Sporton, A Voskoboinik, D Blusztein, JA Mariani, G Lee, AJ Taylor, JM Kalman, PM Kistler

Journal of Cardiovascular Electrophysiology | WILEY-BLACKWELL | Published : 2016

DOI: 10.1111/jce.12899

Download PDF

Abstract

The Impact of Known Heart Disease on AF Ablation Outcomes Background Catheter ablation for AF is an effective treatment for patients with AF and systolic LV dysfunction; however, the clinical outcome is variable. We evaluated the impact of cardiomyopathy etiology on long-term outcomes post-catheter ablation. Methods Patients undergoing AF ablation across 3 centers (2 Australian, 1 UK) from 2002 to 2014, with LVEF<45% were evaluated. Patients were stratified into those with known heart disease as a cause of cardiomyopathy (KHD), and those with idiopathic dilated cardiomyopathy (IDCM). Results One hundred and one patients (IDCM = 77, KHD = 24) with AF and LVEF <45% underwent AF ablation. The K..

View full abstract

University of Melbourne Researchers

Han Ling Author

Geoffrey Lee Author

Andrew Taylor Author

Jonathan Kalman Author

Grants

Funding Acknowledgements

Drs. Prabhu, Ling, McLellan, and Pathik receive funding from Australian National Health and Medical Research Council (NHMRC) and/or National Heart Foundation of Australia. Dr. Ling has also been supported by a Vincent Family Fairfax Foundation Research Fellowship awarded by the Royal Australasian College of Physicians, and an Australian National Heart Foundation Postdoctoral Fellowship. Drs. Prabhu and McLellan also receive funding from the Baker IDI Heart and Diabetes Research Institute. Professor Kalman is in part supported by the NHMRC. Professor M. Kistler is supported by practitioner fellowships from the NHMRC. This research is supported in part by the Victorian Government's Operational Infrastructure Funding.Dr. Kalman reports participation on research grants supported by Biosense Webster, Medtronic, and St. Jude Medical; other research support from Boston Scientific; and compensation from a speaker's bureau from Medtronic and Biosense Webster. Other authors: No disclosures.